Biocon Limited - Product Pipeline Review - 2016

Published: Sep, 2016 | Pages: 51 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Biocon Limited - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Biocon Limited - Product Pipeline Review - 2016', provides an overview of the Biocon Limited's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Biocon Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Biocon Limited
- The report provides overview of Biocon Limited including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Biocon Limited's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Biocon Limited's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Biocon Limited's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Biocon Limited
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Biocon Limited's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Biocon Limited Snapshot 5
Biocon Limited Overview 5
Key Facts 5
Biocon Limited - Research and Development Overview 6
Key Therapeutic Areas 6
Biocon Limited - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Biocon Limited - Pipeline Products Glance 13
Biocon Limited - Late Stage Pipeline Products 13
Pre-Registration Products/Combination Treatment Modalities 13
Phase III Products/Combination Treatment Modalities 14
Biocon Limited - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Biocon Limited - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Biocon Limited - Drug Profiles 18
adalimumab biosimilar - Drug Profile 18
Product Description 18
Mechanism Of Action 18
R&D Progress 18
bevacizumab biosimilar - Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
BVX-20 - Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
etanercept biosimilar - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
filgrastim - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
insulin aspart - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
insulin glargine - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
insulin human - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
insulin lispro - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
insulin tregopil - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
itolizumab - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Monoclonal Antibody Conjugates for Oncology and Infectious Disease - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
pegfilgrastim - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
trastuzumab biosimilar - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Biocon Limited - Pipeline Analysis 36
Biocon Limited - Pipeline Products by Target 36
Biocon Limited - Pipeline Products by Route of Administration 38
Biocon Limited - Pipeline Products by Molecule Type 39
Biocon Limited - Pipeline Products by Mechanism of Action 40
Biocon Limited - Dormant Projects 42
Biocon Limited - Company Statement 43
Biocon Limited - Locations And Subsidiaries 48
Head Office 48
Other Locations & Subsidiaries 48

Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 50
Disclaimer 51

List of Tables

Biocon Limited, Key Facts 5
Biocon Limited - Pipeline by Indication, 2016 8
Biocon Limited - Pipeline by Stage of Development, 2016 9
Biocon Limited - Monotherapy Products in Pipeline, 2016 10
Biocon Limited - Partnered Products in Pipeline, 2016 11
Biocon Limited - Partnered Products/ Combination Treatment Modalities, 2016 12
Biocon Limited - Pre-Registration, 2016 13
Biocon Limited - Phase III, 2016 14
Biocon Limited - Phase II, 2016 15
Biocon Limited - Phase I, 2016 16
Biocon Limited - Preclinical, 2016 17
Biocon Limited - Pipeline by Target, 2016 37
Biocon Limited - Pipeline by Route of Administration, 2016 38
Biocon Limited - Pipeline by Molecule Type, 2016 39
Biocon Limited - Pipeline Products by Mechanism of Action, 2016 41
Biocon Limited - Dormant Developmental Projects,2016 42
Biocon Limited, Other Locations 48
Biocon Limited, Subsidiaries 48